Wockhardt Limited (BOM:532300)

India flag India · Delayed Price · Currency is INR
1,476.85
-69.60 (-4.50%)
At close: Aug 6, 2025
-4.50%
Market Cap239.21B
Revenue (ttm)30.35B
Net Income (ttm)-470.00M
Shares Outn/a
EPS (ttm)-3.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume78,822
Average Volume41,910
Open1,515.25
Previous Close1,546.45
Day's Range1,466.00 - 1,520.30
52-Week Range835.15 - 1,870.00
Betan/a
RSI30.92
Earnings DateAug 8, 2025

About Wockhardt

Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an anti... [Read more]

Industry Pharmaceutical Preparations
Founded 1967
Employees 2,296
Stock Exchange Bombay Stock Exchange
Ticker Symbol 532300
Full Company Profile

Financial Performance

In 2024, Wockhardt's revenue was 30.35 billion, an increase of 7.24% compared to the previous year's 28.30 billion. Losses were -470.00 million, -89.85% less than in 2023.

Financial Statements

News

There is no news available yet.